Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis

Aphthous Stomatitis Clinical Trial

Official title:

National, Multicenter, Randomized, Double-blind, Pilot Study to Evaluate the Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05772338
• Other study ID #: BNP105-P-0123
• Status: Recruiting
• Phase: N/A
• Start date: January 22, 2024
• Est. completion date: April 2025

Study information

• Verified date: February 2023
• Source: EMS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of BNP105 in the treatment of recurrent aphthous stomatitis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 102
• Est. completion date: April 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;

• Age greater than or equal to 12 years;

• One minor recurrent aphthous stomatitis with onset of symptoms within 48 hours;

• Moderate to severe baseline pain, with VAS = 60 mm (EVA scale 0-100 mm).

Exclusion Criteria:

• Any clinical findings that, in the judgment of the investigator, may interfere with the safety of research participants;

• Participants diagnosed with: Behcet's disease, rheumatoid arthritis, systemic lupus erythematosus, reactive arthritis, Reiter's syndrome, Crohn's disease, ulcerative colitis);

• Participants with diseases that affect healing (e.g. diabetes);

• Immunocompromised participants;

• Participants with aphthous herpetiform ulceration or major aphthous ulceration;

• Participants using medication to treat oral ulcerations (systemic or local);

• Participants who used analgesics or anti-inflammatory drugs in the 6 hours prior to the beginning of the study;

• Participants who used systemic antibiotics in the 2 weeks prior to the beginning of the study;

• Participants using medications that can confuse pain assessment (psychotropics, antidepressants and sedative-hypnotics), except when on a stable dose for at least 30 days prior to the screening visit, and the dose cannot be changed during the clinical trial;

• Participants with current smoking habits.

• Participants who are pregnant, breastfeeding or planning to get pregnant or female participants with the potential to become pregnant who are not using a reliable method of contraception;

• Known hypersensitivity to the formula components used during the clinical trial;

• Participants with current or medical history of cancer in the last 5 years;

• Participants who participated in other research protocol in the last 12 months, unless the investigator judges that there may be a direct benefit to it.

Related Conditions & MeSH terms

• Aphthous Stomatitis
• Stomatitis
• Stomatitis, Aphthous

Intervention

Drug:
• BNP105 (25 + 25 + 15)
BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.

Other:
• Placebo
Placebo. Up to six applications per day.

Locations

Country	Name	City	State
Brazil	EMS	Hortolândia	São Paulo
Brazil	Cecip Jau - Centro de Estudos Clinicos Do Interior Paulista Ltda	Jau	SP

Sponsors (1)

Lead Sponsor	Collaborator
EMS

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the change in pain intensity after the first application.	Difference in pain intensity 3 and 10 minutes after the first application of the medication compared to baseline, measured by the VAS scale. The VAS consists of a 100 mm line, with two end points representing 0 ("no pain") and 100 (Worst Possible Pain").	3 and 10 minutes
Secondary	To assess the change in pain intensity after 3 days of treatment.	Difference in pain intensity after 3 days of treatment compared to baseline. Pain intensity will be evaluated by the Visual Analogue Scale (VAS). The VAS consists of a 100 mm line, with two end points representing 0 ("no pain") and 100 (Worst Possible Pain").	3 days
Secondary	To assess the pain intensity daily after breakfast, lunch and dinner.	Pain intensity will be evaluated daily after breakfast, lunch and dinner by the Numeric Pain Rating Scale (NPRS). The NPRS is an 11-point scale scored from 0-10 representing 0 ("no pain") and 10 (Worst Possible Pain").	7 days
Secondary	To assess the pain intensity daily at night.	Pain intensity will be evaluated daily at night by the Numeric Pain Rating Scale (NPRS). The NPRS is an 11-point scale scored from 0-10 representing 0 ("no pain") and 10 (Worst Possible Pain").	7 days
Secondary	To assess the oral health-related quality of life	The oral health-related quality of life will be evaluated daily at night by the adapted Oral Health Impact Profile (OHIP) questionary.	7 days
Secondary	Percentage of participants healed after 3 days of treatment.	Percentage of participants healed after 3 days of treatment, defined as ulcer diameter = 0 mm and pain intensity = 0, measured by the VAS scale. The VAS consists of a 100 mm line, with two end points representing 0 ("no pain") and 100 (Worst Possible Pain").	3 days
Secondary	Percentage of participants with no pain after 3 days of treatment.	Percentage of participants with no pain after 3 days of treatment, defined as pain intensity = 0, measured by the VAS scale. The VAS consists of a 100 mm line, with two end points representing 0 ("no pain") and 100 (Worst Possible Pain").	3 days
Secondary	Global assessment of treatment by participant after 3 days of treatment	The global evaluation of the treatment after 3 days of treatment will be evaluated by the categorical scale of 5 points representing 0 = very bad, 1 = bad, 2 = indifferent, 3 = good and 4 = very good.	3 days